Alaunos Therapeutics, Inc. current report, Q3 FY2025

Business Context and Reporting Period

This Form 8-K filing by Alaunos Therapeutics, Inc. (TCRT) is dated August 19, 2025. The report addresses a regulatory event concerning the Company's compliance with Nasdaq Capital Market listing requirements.

Key Financial Metrics

  • Stockholders' Equity (as of June 30, 2025): $3.66 million (reported in Form 10-Q).
  • Stockholders' Equity (as of December 31, 2024): $2.06 million (reported in Form 10-K).
  • Nasdaq Minimum Equity Requirement: $2.5 million.
  • Revenue, Profit, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for these metrics beyond the stockholders' equity figures cited.

Material Changes

The Company previously received a notice on April 7, 2025, stating non-compliance with Nasdaq Listing Rules due to stockholders' equity falling below the $2.5 million threshold. The material change reported in this filing is the restoration of compliance. Based on the increase in stockholders' equity to $3.66 million as of June 30, 2025, Nasdaq has confirmed the Company now meets the continued listing requirements.

Outlook, Risks, and Management Commentary

Management Commentary: The Company submitted a compliance plan within the permitted 45-day window following the initial notice. The Nasdaq Listing Qualifications staff has determined the matter is closed.

Risks and Contingencies: The primary risk addressed was potential delisting due to insufficient stockholders' equity. This risk has been mitigated as of the filing date. No other unusual items or forward-looking guidance are detailed in this specific report.

Investor Verification Checklist

  • Verify the $3.66 million stockholders' equity figure in the Form 10-Q for the period ended June 30, 2025.
  • Confirm the Company's current trading status on The Nasdaq Stock Market LLC.
  • Review the Form 10-K for the year ended December 31, 2024, to understand the prior equity position of $2.06 million.
  • Monitor future filings for any new compliance notices regarding market value of listed securities or net income requirements.